Un ongle d'inclusion: une complication de la cure chirurgicale d'ongle incarné selon la technique de Zadik.

Case ReportsJournal Articleinfo:eu-repo/semantics/publishe

Actinic granulomas and relapsing polychondritis.

A patient developed concomitantly chondritis of the two auricles, diffuse cutaneous vasculitis and actinic granulomas. Alterations in skin and cartilage were prominent in the elastic tissue. Anticollagen type II antibodies were absent from the serum and there was no deposit of immunoreactants in cartilages. In this form of relapsing polychondritis, the pathomechanism resembles that of diffuse actinic arteritis as proposed by O'Brien. It is concluded that relapsing polychondritis may represent a heterogeneous syndrome with regard to its pathogenesis

Ostéo-onychodysplasie héréditaire (nail patella syndrome).

Journal ArticleReviewinfo:eu-repo/semantics/publishe

Cas clinique : Toxidermie à l'héparine

Nous rapportons l'histoire clinique d'une patiente de 74 ans, hospitalisée pour fibrillation auriculaire "de novo" qui développe des lésions cutanées généralisées, douloureuses, nécrotiques, bullo-hémorragiques sur fond érythémateux et apparues quelques jours après l'administration d'héparine de bas poids moléculaire. le diagnostic de toxidermie est confirmé par une biopsie cutanée. À la biologie sanguine, une réduction de 30% de nombre de plaquettes par rapport à la valeur à l'admission est décelée. L'héparine est alors stoppée et un traitement par anti-coagulant oral de type coumarinique est instauré. Dans le décours, les lésions cutanées régressent rapidement. Etant donné les caractéristiques des lésions, le délai entre l'apparition des lésions et l'introduction de l'héparine de bas poids moléculaire, la chute du taux de plaquettes et la régression des lésions à l'arrêt de l'héparine, on peut conclure à une réaction d'hypersensibilité de type II (classification de Gell et Coombs) à l'héparine. La prise en charge consiste en l'arrêt du traitement par héparine et un relais par anticoagulant non hépariné (anti-vitamine K, inhibiteur direct de la thrombine ou héparinoïde). On peut également doser le taux d'anticorps dirigés contre le complexe héparine-facteur plaquettaire 4

Un ongle d’inclusion: une complication de la cure chirurgicale d’ongle incarné

Journées Dermatologiques de paris (Paris, 7-11.12.2004). Ann Dermatol Venereol 2004; 131: S100 (Poster 48)info:eu-repo/semantics/publishe

Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria

BACKGROUND: Chronic urticaria is known to debilitate a person's quality of life via sleep disruption, itching lesions, fatigue, social isolation, energy loss and emotional/sexual difficulties. Once-daily desloratadine significantly improved the signs and symptoms of CIU. OBJECTIVE: Assess the effect of desloratadine 5 mg once daily on the quality of life of patients suffering of chronic idiopathic urticaria (CIU). Study population One-hundred twenty-one consecutive patients with CIU present for at least 6 weeks prior to inclusion and with a current flare of at least 3 weeks, were included in the study in 24 Belgian centres. RESULTS: The mean dermatology life quality index (DLQI) significantly decreased from baseline to day 7 and further to day 42. Sixty per cent and 77% of patients had a clinically significant change (i.e. a decrease of at least 2 points) at day 7 or day 42, respectively, as compared with that of day 0. Change in pruritus and size of the hives significantly correlated with the change in the score of the quality of life. One-third of patients experienced complete relief whereas in 1 of 10 patients no effect was experienced. CONCLUSIONS: Desloratadine significantly improves the quality of life of patients with chronic idiopathic urticaria as reflected by the dermatology life quality index (DLQI)

Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria.

BACKGROUND: Chronic urticaria is known to debilitate a person's quality of life via sleep disruption, itching lesions, fatigue, social isolation, energy loss and emotional/sexual difficulties. Once-daily desloratadine significantly improved the signs and symptoms of CIU. OBJECTIVE: Assess the effect of desloratadine 5 mg once daily on the quality of life of patients suffering of chronic idiopathic urticaria (CIU). Study population One-hundred twenty-one consecutive patients with CIU present for at least 6 weeks prior to inclusion and with a current flare of at least 3 weeks, were included in the study in 24 Belgian centres. RESULTS: The mean dermatology life quality index (DLQI) significantly decreased from baseline to day 7 and further to day 42. Sixty per cent and 77% of patients had a clinically significant change (i.e. a decrease of at least 2 points) at day 7 or day 42, respectively, as compared with that of day 0. Change in pruritus and size of the hives significantly correlated with the change in the score of the quality of life. One-third of patients experienced complete relief whereas in 1 of 10 patients no effect was experienced. CONCLUSIONS: Desloratadine significantly improves the quality of life of patients with chronic idiopathic urticaria as reflected by the dermatology life quality index (DLQI)